Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies

Journal of Clinical Oncology

Volumn 23, Issue 27, 2005, Pages 6719-6729

  Kreitman, Robert J ^a   Squires, David R ^a   Stetler Stevenson, Maryalice ^a   Noel, Pierre ^a   FitzGerald, David J P ^a   Wilson, Wyndham H ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CELECOXIB; CHLORAMBUCIL; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETANERCEPT; ETOPOSIDE; FLAVOPIRIDOL; FLUDARABINE; IBUPROFEN; IFOSFAMIDE; IMMUNOTOXIN; IMMUNOTOXIN BL22; INDOMETACIN; INTERFERON; MESNA; METHYLPREDNISOLONE; MITOXANTRONE; NAPROXEN; NEUTRALIZING ANTIBODY; PENTOSTATIN; PREDNISONE; RITUXIMAB; STEROID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; ANTIBODY; ENTEROTOXIN; RFB4(DSFV) PE38 RECOMBINANT IMMUNOTOXIN; RFB4(DSFV)-PE38 RECOMBINANT IMMUNOTOXIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER REGRESSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG MEGADOSE; DRUG TOLERABILITY; DYSPEPSIA; EDEMA; FATIGUE; FEMALE; FEVER; FLUSHING; HAIRY CELL LEUKEMIA; HEADACHE; HEMATURIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN CELL; HYPOALBUMINEMIA; HYPOTENSION; IMMUNOGENICITY; INFLAMMATION; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PLASMAPHERESIS; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEINURIA; REACTION TIME; SIDE EFFECT; SWEATING; TREATMENT RESPONSE; VASCULAR DISEASE; VASCULAR LEAK; VOMITING; WEIGHT GAIN; B CELL LEUKEMIA; COMPARATIVE STUDY; DRUG ADMINISTRATION; FOLLOW UP; HOSPITALIZATION; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENTEROTOXINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTOXINS; INFUSIONS, INTRAVENOUS; LEUKEMIA, B-CELL, CHRONIC; LEUKEMIA, HAIRY CELL; LYMPHOMA, NON-HODGKIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 27244448693     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.11.437     Document Type: Article

References (51)

1. Christiansen J, Rajasekaran AK: Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol Cancer Ther 3:1493-1501, 2004
2. Weiner GJ, Link BK: Antibody therapy of lymphoma. Adv Pharmacol 51:229-253, 2004
3. Lin TS, Byrd JC: Monoclonal antibody therapy in lymphoid leukemias. Adv Pharmacol 51: 127-167, 2004
4. McDermott DF, Atkins MB: Application of IL-2 and other cytokines in renal cancer. Expert Opin Biol Ther 4:455-468, 2004
5. Majhail NS, Hussein M, Olencki TE, et al: Phase I trial of continuous infusion recombinant human interleukin-4 in patients with cancer. Invest New Drugs 22:421-426, 2004
6. Burke JM, Jurcic JG: Radioimmunotherapy of leukemia. Adv Pharmacol 51:185-208, 2004
7. Cheson BD: Radioimmunotherapy of non-Hodgkin lymphomas. Blood 101:391-398, 2003
8. Linenberger ML: CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: Progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 19:176-182, 2005
9. Law CL, Cerveny CG, Gordon KA, et al: Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin Cancer Res 10:7842-7851, 2004
10. FitzGerald DJ, Kreitman R, Wilson W, et al: Recombinant immunotoxins for treating cancer. Int J Med Microbiol 293:577-582, 2004
11. Frankel AE, Neville DM, Bugge TA, et al: Immunotoxin therapy of hematologic malignancies. Semin Oncol 30:545-557, 2003
12. Dang NH, Hagemeister FB, Pro B, et al: Phase II study of denileukin diftitox for relapsed/ refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 22:4095-4102, 2004
13. Kreitman RJ, Pastan I: Immunobiologic treatments of hairy-cell leukemia. Best Pract Res Clin Haematol 16:117-133, 2003
14. Amlot PL, Stone MJ, Cunningham D, et al: A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 82:2624-2633, 1993
15. Sausville EA, Headlee D, Stetler-Stevenson M, et al: Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A phase I study. Blood 85:3457-3465, 1995
16. Vitetta ES, Stone M, Amlot P, et al: Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 51:4052-4058, 1991
17. Clark EA: CD22, a B cell-specific receptor, mediates adhesion and signal transduction. J Immunol 150:4715-4718, 1993
18. Mansfield E, Amlot P, Pastan I, et al: Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood 90:2020-2026, 1997
19. Reiter Y, Brinkmann U, Kreitman RJ, et al: Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry 33:5451-5459, 1994
20. Reiter Y, Kreitman RJ, Brinkmann U, et al: Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin. Int J Cancer 58:142-149, 1994
21. Allured VS, Collier RJ, Carroll SF, et al: Structure of exotoxin A of Pseudomonas aeruginosa at 3.0 Angstrom resolution. Proc Natl Acad Sci U S A 83:1320-1324, 1986
22. Hessler JL, Kreitman RJ: An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor. Biochemistry 36:14577-14582, 1997
23. Chiron MF, Fryling CM, FitzGerald DJ: Cleavage of Pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver. J Biol Chem 269:18167-18176, 1994
24. 280 generates the enzymatically active fragment which translocates to the cytosol. J Biol Chem 267:25396-25401, 1992
25. Kreitman RJ, Pastan I: Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem J 307:29-37, 1995
26. Theuer C, Kasturi S, Pastan I: Domain II of Pseudomonas exotoxin A arrests the transfer of translocating nascent chains into mammalian microsomes. Biochemistry 33:5894-5900, 1994
27. Theuer CP, Buchner J, FitzGerald D, et al: The N-terminal region of the 37-kDa translocated fragment of Pseudomonas exotoxin A aborts translocation by promoting its own export after microsomal membrane insertion. Proc Natl Acad Sci U S A 90:7774-7778, 1993
28. Kreitman RJ, Margulies I, Stetler-Stevenson M, et al: Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) towards fresh malignant cells from patients with B-cell leukemias. Clin Cancer Res 6:1476-1487, 2000
29. Kreitman RJ, Wang QC, FitzGerald DJP, et al: Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by Cynomolgus monkeys. Int J Cancer 81:148-155, 1999
30. Kreitman RJ, Wilson WH, Bergeron K, et al: Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia. N Engl J Med 345:241-247, 2001
31. Goodman GR, Burian C, Koziol JA, et al: Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 21:891-896, 2003
32. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17:1244-1253, 1999
33. Juliusson G, Liliemark J: Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2′-deoxyadenosine (CdA): relation to opportunistic infections. Blood 79: 888-894, 1992
34. Hoffman MA, Janson D, Rose E, et al: Treatment of hairy-cell leukemia with cladribine: Response, toxicity, and long-term follow-up. J Clin Oncol 15:1138-1142, 1997
35. Blasinska-Morawiec M, Robak T, Krykowski E, et al: Hairy cell leukemia-variant treated with 2-chlorodeoxyadenosine-a report of three cases. Leuk Lymphoma 25:381-385, 1997
36. Matutes E, Wotherspoon A, BritoBabapulle V, et al: The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia 15:184-186, 2001
37. Moake JL: Thrombotic microangiopathies. N Engl J Med 347:589-600, 2002
38. Tallman MS, Hakimian D, Kopecky KJ, et al: Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. Clin Cancer Res 5:1665-1670, 1999
39. Wheaton S, Tallman MS, Hakimian D, et al: Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 87:1556-1560, 1996
40. Matutes E, Meeus P, McLennan K, et al: The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: A long-term follow-up study. Br J Haematol 98:375-383, 1997
41. Zak P, Chrobak L, Dedic K: Minimal residual disease, its detection and significance in hairy-cell leukemia. Acta Medica (Hradec Kralove) 42:85-88, 1999
42. Sausville JE, Salloum R, Sorbara L, et al: Minimal residual disease detection in hairy cell leukemia: Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene. Am J Clin Pathol 119:213-217, 2002
43. Seymour JF, Kurzrock R, Freireich EJ, et al: 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood 83:2906-2911, 1994
44. Seymour JF, Talpaz M, Kurzrock R: Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up. Leukemia 11:42-47, 1997
45. Filleul B, Delannoy A, Ferrant A, et al: A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia 8:1153-1156, 1994
46. Carbone A, Reato G, Di Celle PF, et al: Disease eradication in hairy cell leukemia patients treated with 2-chlorodeoxyadenosine. Leukemia 8:2019-2020, 1994 (letter)
47. Hagberg H, Lundholm L: Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br J Haematol 115:609-611, 2001
48. Lauria F, Lenoci M, Annino L, et al: Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica 86:1046-1050, 2001
49. Nieva J, Bethel K, Saven A: Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 102:810-813, 2003
50. Thomas DA, O'Brien S, Bueso-Ramos C, et al: Rituximab in relapsed or refractory hairy cell leukemia. Blood 102:3906-3911, 2003
51. Salvatore G, Beers R, Margulies I, et al: Improved Cytotoxic activity towards cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res 8:995-1002, 2002